US6458772B1
(en)
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
WO1999009031A1
(en)
*
|
1997-08-15 |
1999-02-25 |
Medivir Ab |
Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv)
|
GB8725939D0
(en)
*
|
1987-11-05 |
1987-12-09 |
Wellcome Found |
Therapeutic compounds
|
GB8829571D0
(en)
*
|
1988-12-19 |
1989-02-08 |
Wellcome Found |
Antiviral compounds
|
US5677308A
(en)
*
|
1996-12-19 |
1997-10-14 |
Lerner; A. Martin |
Method for alleviating spasmodic torticollis
|
US6537997B1
(en)
|
1997-02-18 |
2003-03-25 |
A. Martin Lerner |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US5872123A
(en)
|
1997-02-18 |
1999-02-16 |
Lerner; A. Martin |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US6399622B1
(en)
|
1997-02-18 |
2002-06-04 |
A. Martin Lerner |
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
|
US20020128301A1
(en)
*
|
1998-02-13 |
2002-09-12 |
Medivir AB |
Non-nucleoside reverse transcriptase inhibitors
|
US6444652B1
(en)
*
|
1998-08-10 |
2002-09-03 |
Novirio Pharmaceuticals Limited |
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
|
AU5475799A
(en)
*
|
1998-08-10 |
2000-03-06 |
Centre National De La Recherche Scientifique |
Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
|
US6107303A
(en)
*
|
1999-03-15 |
2000-08-22 |
Demarco; Charlene C. |
Treatment of Epstein Barr infection
|
US6448256B1
(en)
|
1999-05-24 |
2002-09-10 |
University Of Massachusetts |
Antibiotic prodrugs
|
GB0010446D0
(en)
*
|
2000-04-28 |
2000-06-14 |
Glaxo Wellcome Kk |
Pharmaceutical formulation
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
*
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
US6875751B2
(en)
*
|
2000-06-15 |
2005-04-05 |
Idenix Pharmaceuticals, Inc. |
3′-prodrugs of 2′-deoxy-β-L-nucleosides
|
US20030212051A1
(en)
*
|
2001-04-06 |
2003-11-13 |
Polli James E |
Bile acid containing prodrugs with enhanced bioavailabilty
|
US6849736B2
(en)
*
|
2001-09-07 |
2005-02-01 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of valacyclovir hydrochloride
|
AU2002330154A1
(en)
*
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
AU2002348022B2
(en)
*
|
2001-11-05 |
2006-06-15 |
Glaxo Group Limited |
Anhydrous crystal form of valaciclovir hydrochloride
|
CA2649826A1
(en)
*
|
2001-11-14 |
2003-05-22 |
Teva Pharmaceutical Industries Ltd. |
Synthesis and purification of valacyclovir
|
US7105527B2
(en)
*
|
2001-12-14 |
2006-09-12 |
Otto Michael J |
N4-acylcytosine nucleosides for treatment of viral infections
|
EP1569658A4
(en)
*
|
2001-12-20 |
2007-05-30 |
Pharmassett Ltd |
TREATMENT OF EPSTEIN-BARR VIRUS, INFECTION WITH KAPOSI-ASSOCIATED SARCOMA HERPESVIRUS AND ABNORMAL CELL PROLIFERATION
|
SE521676C2
(sv)
*
|
2002-01-02 |
2003-11-25 |
Dilafor Ab |
Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
|
CA2476279A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Lieven J. Stuyver |
Modified fluorinated nucleoside analogues
|
EP2316469A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
AU2003240213A1
(en)
*
|
2002-06-24 |
2004-01-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
|
EP1536804A4
(en)
*
|
2002-06-28 |
2007-10-31 |
Idenix Cayman Ltd |
2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
|
EP2799442A1
(en)
|
2002-06-28 |
2014-11-05 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
CA2490200C
(en)
|
2002-06-28 |
2012-01-03 |
Idenix (Cayman) Limited |
2' and 3'-nucleoside prodrugs for treating flaviviridae infections
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
TWI244393B
(en)
*
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
US20050043329A1
(en)
*
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
AU2003278816A1
(en)
*
|
2002-09-13 |
2004-04-30 |
Idenix (Cayman) Limited |
ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
|
CN1319972C
(zh)
*
|
2002-10-16 |
2007-06-06 |
特瓦制药工业有限公司 |
在盐酸伐昔洛韦结晶中减少残留醇类物质的方法
|
US20050059684A1
(en)
*
|
2002-10-16 |
2005-03-17 |
Ben-Zion Dolitzky |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
CA2501557A1
(en)
*
|
2002-10-16 |
2004-04-29 |
Teva Pharmaceutical Industries Ltd |
Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
TWI332507B
(en)
*
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
WO2004052892A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Texcontor Etablissement |
Anhydrous crystalline form of valacyclovir hydrochloride
|
CN1742018A
(zh)
*
|
2002-12-10 |
2006-03-01 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的核苷衍生物
|
CA2509687C
(en)
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
MXPA05006865A
(es)
*
|
2002-12-23 |
2005-12-12 |
Idenix Cayman Ltd |
Proceso para la produccion de profarmacos 3'-nucleosidos.
|
EP3025718A1
(en)
*
|
2003-01-14 |
2016-06-01 |
Gilead Sciences, Inc. |
Compositions and methods for combination antiviral therapy
|
US7582748B2
(en)
*
|
2003-03-20 |
2009-09-01 |
Microbiologica Quimica E Farmaceutical Ltd. |
Methods of manufacture of 2′-deoxy-β-L-nucleosides
|
US7595390B2
(en)
*
|
2003-04-28 |
2009-09-29 |
Novartis Ag |
Industrially scalable nucleoside synthesis
|
AU2003232719A1
(en)
*
|
2003-05-30 |
2005-01-21 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Novel crystalline forms of valacyclovir hydrochloride
|
BRPI0410846B8
(pt)
|
2003-05-30 |
2021-05-25 |
Gilead Pharmasset Llc |
nucleosídeo e composição farmacêutica compreendendo o mesmo
|
US20050085491A1
(en)
*
|
2003-06-02 |
2005-04-21 |
Igor Lifshitz |
Novel crystalline forms of valacyclovir hydrochloride
|
NZ544634A
(en)
|
2003-06-30 |
2009-10-30 |
Idenix Cayman Ltd |
Synthesis of beta-l-2-deoxy nucleosides
|
US20050025839A1
(en)
*
|
2003-07-28 |
2005-02-03 |
Polli James Edward |
Formulation approach to enhance transporter-mediated drug uptake
|
US20070167353A1
(en)
*
|
2003-10-24 |
2007-07-19 |
John Hilfinger |
Prodrug composition
|
US20050137141A1
(en)
*
|
2003-10-24 |
2005-06-23 |
John Hilfinger |
Prodrug composition
|
US7253175B2
(en)
*
|
2003-11-13 |
2007-08-07 |
Barnet Liberman |
Method for treating athlete's foot
|
CN1980657A
(zh)
|
2004-05-05 |
2007-06-13 |
耶鲁大学 |
新颖的抗病毒赛菊宁黄质类似物
|
AU2005256963A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
CN101068814A
(zh)
*
|
2004-09-04 |
2007-11-07 |
特瓦制药工业有限公司 |
分离的伐昔洛韦杂质,制备伐昔洛韦杂质的方法及其作为参比标准物的应用
|
ES2769377T3
(es)
|
2004-09-14 |
2020-06-25 |
Gilead Pharmasset Llc |
Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
|
US20060178512A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Cheruthur Govindan |
Method for preparing amino acid esters of nucleoside analogues
|
ATE546451T1
(de)
*
|
2005-05-25 |
2012-03-15 |
Lilly Co Eli |
Cyclopropancarbonsäureester von acyclovir
|
TWI375560B
(en)
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
TWI471145B
(zh)
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
EP1746098A1
(en)
*
|
2005-07-21 |
2007-01-24 |
SOLMAG S.p.A. |
Valacyclovir polymorphs and a process for the preparation thereof
|
US20070112193A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Khunt Mayur D |
Valacyclovir process
|
WO2007075876A2
(en)
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
GB0605344D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Pliva Istrazivanje I Razvoj D |
Pharmaceutically acceptable salts and polymorphic forms
|
CN101534848B
(zh)
*
|
2006-09-19 |
2013-07-17 |
亚洲大学校产学协力团 |
抗动物病毒的抗病毒剂
|
US20080167325A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Bs Praveen Kumar |
Valacyclovir compositions
|
JP2010515747A
(ja)
*
|
2007-01-12 |
2010-05-13 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
テトラヒドロビオプテリンプロドラッグ
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US20080281099A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Mayur Devjibhai Khunt |
Process for purifying valacyclovir hydrochloride and intermediates thereof
|
US20090076039A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched valacyclovir
|
CA2711160A1
(en)
|
2008-01-03 |
2009-07-16 |
Biomarin Pharmaceutical Inc. |
Pterin analog for treating bh4 responsive condition
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US20110059921A1
(en)
*
|
2008-03-27 |
2011-03-10 |
Ektar Therapeutics |
Oligomer-Nitrogenous Base Conjugates
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
CN102753563A
(zh)
*
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
AU2009329867B2
(en)
*
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
CN102584825B
(zh)
*
|
2011-01-17 |
2014-04-02 |
四川科伦药物研究有限公司 |
一种合成盐酸伐昔洛韦的方法
|
EP2852592A4
(en)
*
|
2011-11-25 |
2015-12-23 |
Piramal Entpr Ltd |
PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US20140100238A1
(en)
|
2012-10-04 |
2014-04-10 |
Ohio State University |
Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
|
US20140213600A1
(en)
*
|
2013-01-29 |
2014-07-31 |
Lily Hsiao |
Medicament for treating peripheral neuropathies
|
TW201429475A
(zh)
*
|
2013-01-29 |
2014-08-01 |
Li-Ly Hsiao |
使用抗病毒藥治療末稍神經病變之疾病
|
PT3650014T
(pt)
|
2013-08-27 |
2021-12-27 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
CN115745997A
(zh)
*
|
2022-11-30 |
2023-03-07 |
湖北省宏源药业科技股份有限公司 |
一种高纯度伐昔洛韦杂质h制备方法
|